Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-004
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
FBR Capital Cuts Price Target After Genocea Biosciences (GNCA) Reports Disappointing GEN-004 Data
October 19, 2015 1:22 PM EDTFBR Capital reiterated an Outperform rating on Genocea Biosciences (NASDAQ: GNCA), and cut the price target to $17.00 (from $20.00), following top-line Phase II data for GEN-004. Although the data showed consistent reductions in the rate and density of colonization compared to placebo, neither endpoint reached statistical... More
Genocea Biosciences (GNCA) PT Lowered to $15 at Needham & Company
October 19, 2015 10:03 AM EDTNeedham & Company analyst Alan Carr lowered his price target on Genocea Biosciences (NASDAQ: GNCA) to $15.00 (from $22.00) announced results from its GEN-004 Phase 2 Pneumococcal Pneumonia challenge trial this morning. The firm maintained a Buy rating.
Carr commented, "Although a trend towards improvement over placebo was... More
Genocea Biosciences (GNCA) Announces GEN-004 Phase 2a Results Not Statistically Significant
October 19, 2015 7:02 AM EDTGenocea Biosciences (NASDAQ: GNCA) announced that top-line results from a Phase 2a clinical trial for GEN-004, its universal vaccine candidate against pneumococcus, showed consistent reductions versus placebo in the pre-specified endpoints of the rate and density of colonization, but that neither of the endpoints achieved statistical significance. GEN-004 was safe and well tolerated by subjects.
We are currently working with our advisors to better understand these results and to determine a next step for this program. While we did not hit statistical significance in this study, the consistent apparent effect gives us... More
